Collaborative stepped care for anxiety disorders in primary care: aims and design of a randomized controlled trial.
BACKGROUND
Panic disorder (PD) and generalized anxiety disorder (GAD) are two of the most disabling and costly anxiety disorders seen in primary care. However, treatment quality of these disorders in primary care generally falls beneath the standard of international guidelines. Collaborative stepped care is recommended for improving treatment of anxiety disorders, but cost-effectiveness of such an intervention has not yet been assessed in primary care. This article describes the aims and design of a study that is currently underway. The aim of this study is to evaluate effects and costs of a collaborative stepped care approach in the primary care setting for patients with PD and GAD compared with care as usual.


METHODS
The study is a two armed, cluster randomized controlled trial. Care managers and their primary care practices will be randomized to deliver either collaborative stepped care (CSC) or care as usual (CAU). In the CSC group a general practitioner, care manager and psychiatrist work together in a collaborative care framework. Stepped care is provided in three steps: 1) guided self-help, 2) cognitive behavioral therapy and 3) antidepressant medication. Primary care patients with a DSM-IV diagnosis of PD and/or GAD will be included. 134 completers are needed to attain sufficient power to show a clinically significant effect of 1/2 SD on the primary outcome measure, the Beck Anxiety Inventory (BAI). Data on anxiety symptoms, mental and physical health, quality of life, health resource use and productivity will be collected at baseline and after three, six, nine and twelve months.


CONCLUSIONS
It is hypothesized that the collaborative stepped care intervention will be more cost-effective than care as usual. The pragmatic design of this study will enable the researchers to evaluate what is possible in real clinical practice, rather than under ideal circumstances. Many requirements for a high quality trial are being met. Results of this study will contribute to treatment options for GAD and PD in the primary care setting. Results will become available in 2011.


BACKGROUND
NTR1071.
Muntingh
Anna D T
AD
Netherlands Institute of Mental Health and Addiction (Trimbos-institute), Utrecht, the Netherlands. amuntingh@trimbos.nl
van der Feltz-Cornelis
Christina M
CM
van Marwijk
Harm W J
HW
Spinhoven
Philip
P
Assendelft
Willem J J
WJ
de Waal
Margot W M
MW
Hakkaart-van Roijen
Leona
L
Adèr
Herman J
HJ
van Balkom
Anton J L M
AJ
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy / Q000628:therapy*; D015928:Cognitive Behavioral Therapy; D003299:Cooperative Behavior; D003362:Cost-Benefit Analysis; D005194:Family Practice; D005260:Female; D006801:Humans; D007400:Interprofessional Relations; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D016584:Panic Disorder / Q000628:therapy; D010346:Patient Care Management; D011320:Primary Health Care / Q000191:economics / Q000379:methods*; D011570:Psychiatry; D012107:Research Design
D000928:Antidepressive Agents